

| OMB APPROVAL             |                     |
|--------------------------|---------------------|
| OMB Number:              | 3235-0287           |
| Estimated average burden | hours per response: |
|                          | 0.5                 |

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

|  |   |  |
|--|---|--|
| 1. Name and Address of Reporting Person*<br><u>CRANDELL KEITH</u><br><hr/> (Last) (First) (Middle)<br>8755 W. HIGGINS ROAD, SUITE 1025<br><hr/> (Street)<br>CHICAGO IL 60631<br><hr/> (City) (State) (Zip)   | 2. Issuer Name and Ticker or Trading Symbol<br><u>Sana Biotechnology, Inc. [ SANA ]</u> | 5. Relationship of Reporting Person(s) to Issuer<br>(Check all applicable)<br>Director <input checked="" type="checkbox"/> 10% Owner<br>Officer (give title below) Other (specify below) |
|  | 3. Date of Earliest Transaction (Month/Day/Year)<br>02/08/2024                          |  |
|  | 4. If Amendment, Date of Original Filed (Month/Day/Year)                                | 6. Individual or Joint/Group Filing (Check Applicable Line)<br>Form filed by One Reporting Person<br><input checked="" type="checkbox"/> Form filed by More than One Reporting Person    |
| Rule 10b5-1(c) Transaction Indication<br><input type="checkbox"/> Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. |   |  |

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) |   | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) |            |       | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|------------|-------|---|--|---|
|                                 |                                      |  | Code                           | V | Amount  | (A) or (D) | Price |   |  |   |
| Common Stock                    | 02/08/2024                           |  | P                              |   | 363,637   | A          | \$5.5 | 10,667,387  | I  | See Footnote <sup>(1)(3)</sup>                        |
| Common Stock                    |                                      |  |                                |   |   |            |       | 10,301,250  | I  | See Footnote <sup>(2)(3)</sup>                        |
| Common Stock                    | 02/08/2024                           |  | P                              |   | 727,272   | A          | \$5.5 | 12,446,022  | I  | See Footnote <sup>(4)(6)</sup>                        |
| Common Stock                    | 02/08/2024                           |  | P                              |   | 727,272   | A          | \$5.5 | 12,446,022  | I  | See Footnote <sup>(5)(6)</sup>                        |

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) |   | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) |                 | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|--|-----------------|---|--|--|---|--|
|  |  |                                      |  | Code                           | V |  | Date Exercisable   | Expiration Date |   |  |  |   |  |

1. Name and Address of Reporting Person\*  
CRANDELL KEITH  


---

 (Last) (First) (Middle)  
 8755 W. HIGGINS ROAD, SUITE 1025  


---

 (Street)  
 CHICAGO IL 60631  


---

 (City) (State) (Zip)

1. Name and Address of Reporting Person\*  
BYBEE CLINTON  


---

 (Last) (First) (Middle)  
 8755 W. HIGGINS ROAD, SUITE 1025  


---

 (Street)  
 CHICAGO IL 60631  


---

 (City) (State) (Zip)

|  |         |          |
|--|---------|----------|
| 1. Name and Address of Reporting Person* |         |          |
| <u>Burow Kristina</u>                    |         |          |
| (Last)                                   | (First) | (Middle) |
| 8755 W. HIGGINS ROAD,SUITE 1025          |         |          |
| (Street)                                 |         |          |
| CHICAGO                                  | IL      | 60631    |
| (City) (State) (Zip)                     |         |          |
| 1. Name and Address of Reporting Person* |         |          |
| <u>GILLIS STEVEN</u>                     |         |          |
| (Last)                                   | (First) | (Middle) |
| 8755 W. HIGGINS ROAD, SUITE 1025         |         |          |
| (Street)                                 |         |          |
| CHICAGO                                  | IL      | 60631    |
| (City) (State) (Zip)                     |         |          |

**Explanation of Responses:**

1. Represents shares held directly by ARCH Venture Fund IX, L.P. (ARCH IX). ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX.
2. Represents shares held directly by ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage). ARCH Venture Partners IX Overage, L.P. (AVP IX Overage LP) is the sole general partner of ARCH IX Overage.
3. ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell and Clinton Bybee are managing directors of AVP IX LLC (the AVP IX MDs). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and each of the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC, and the AVP IX MDs each disclaim beneficial ownership except to the extent of any pecuniary interest therein.
4. Represents shares held directly by ARCH Venture Fund X, L.P. (ARCH X). ARCH Venture Partners X, L.P. (AVP X LP) is the sole general partner of ARCH X.
5. Represents shares held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage.
6. ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of each of AVP X LP and AVP X Overage LP. Keith Crandell, Kristina Burow and Steven Gillis are members of the investment committee of AVP X LLC (the AVP X Committee Members). AVP X LP and AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, respectively, AVP X LLC may be deemed to beneficially own the shares held by ARCH X and ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X and ARCH X Overage. AVP X LP, AVP X Overage LP, AVP X LLC, and the AVP X Committee Members each disclaim beneficial ownership except to the extent of any pecuniary interest therein.

**Remarks:**

This Form 4 is one of two reports relating to the same transaction being filed jointly by ARCH IX, AVP IX LP, ARCH IX Overage, AVP IX Overage LP, AVP IX LLC, ARCH X, AVP X LP, ARCH X Overage, AVP X Overage LP, AVP X LLC, Keith Crandell, Clinton Bybee, Kristina Burow and Steven Gillis (collectively, the "Reporting Persons"). Robert Nelsen has direct ownership of Common Stock and is filing his own Form 4 separately.

|   |                   |
|---|-------------------|
| <u>/s/ Keith Crandell, By: Mark McDonnell, attorney in-fact</u> | <u>02/12/2024</u> |
| <u>/s/ Clinton Bybee, By: Mark McDonnell, attorney in-fact</u>  | <u>02/12/2024</u> |
| <u>/s/ Kristina Burow, By: Mark McDonnell, attorney in-fact</u> | <u>02/12/2024</u> |
| <u>/s/ Steven Gillis, By: Mark McDonnell, attorney in-fact</u>  | <u>02/12/2024</u> |
| ** Signature of Reporting Person                                | Date              |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**